GLPwatch
In adults with moderate-to-severe OSA and obesity, tirzepatide reduced apnea-hypopnea events vs. placebo.
Ann Intern Med · 2024
Last updated 2026-08-28| Journal | Ann Intern Med, 2024 |
|---|---|
| Citations | 2 |
| Relative citation ratio | 0.32 |
| NIH percentile | 20 |
| Molecules | tirzepatide |
Abstract
Malhotra A, Grunstein RR, Fietze I, et al; SURMOUNT-OSA Investigators. N Engl J Med. 21 Jun 2024. [Epub ahead of print.] 38912654.
Verbatim abstract via PubMed 39348697 ↗
Related research
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.